The late adverse events of rituximab therapy – rare but there!
Authors:
- 1 January 2009
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 50 (7) , 1083-1095
Abstract
Rituximab, an anti CD20 monoclonal antibody, has now become a cornerstone in the treatment of many CD20 positive hematological malignancies and a variety of autoimmune disorders. In contrast to the acute allergic and cytokine associated reactions, late adverse events of rituximab are indeed uncommon but at the same time probably under-reported. In this review, we detail late adverse events reported since its use in hemato-oncological neoplasias and other disorders. These adverse events include the development of late-onset neutropenia, defects of immune reconstitution with associated immune compromise, infections, progressive multifocal leukoencephalopathy, reactivation of hepatitis, intestinal perforation and interstitial pneumonitis. Possible mechanisms involved in rituximab-associated complications and the pathogenesis of these adverse effects are reviewed and discussed. Evidence based graded recommendations for the management of these adverse effects are proposed.Keywords
This publication has 122 references indexed in Scilit:
- Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trialsAnnals of the Rheumatic Diseases, 2009
- Risk factors for infection in haematology patients treated with rituximabEuropean Journal of Haematology, 2008
- Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximabJournal of Medical Virology, 2008
- Persistent and Relapsing Babesiosis in Immunocompromised PatientsClinical Infectious Diseases, 2008
- Presentation of HCV antigens to naive CD8+T cells: Why the where, when, what and how are important for virus control and infection outcomeClinical Immunology, 2007
- Rituximab‐induced interstitial lung diseaseAmerican Journal of Hematology, 2007
- Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositisJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Monoclonal Antibody Therapy for B-Cell MalignanciesSeminars in Oncology, 2006
- Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemiaCancer, 2004
- The mechanisms of action of rituximab in the elimination of tumor cellsSeminars in Oncology, 2003